Overview

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

Status:
Completed

Trial end date:
2020-10-15

Target enrollment:

Participant gender:

Summary

The purpose of this study was to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborator:

Allergan

Treatments:

Cenicriviroc
TAK-652